Phase II study of cobolimab in combination with dostarlimab for the treatment of advanced hepatocellular carcinoma.

Author:

Acoba Jared David1,Rho Young2,Fukaya Erin1

Affiliation:

1. University of Hawaii Cancer Center, Honolulu, HI;

2. Queen's Medical Center, Honolulu, HI;

Abstract

580 Background: Immunotherapy is the backbone of hepatocellular cancer (HCC) systemic treatments. Preclinical studies have shown that the combination of anti-TIM-3 antibody and anti-PD-1 antibody is more effective than either therapy alone. Early clinical experience shows that the combination of cobolimab (anti-TIM-3) and dostarlimab (anti-PD-1) can be safely administered. Herein we report an interim update to this phase II, single arm study of cobolimab and dostarlimab in patients with untreated advanced HCC. We hypothesize that this combination immune checkpoint inhibitor therapy will increase the overall response rate (ORR) of patients from 20% (historical control) to 35%. Methods: In total, 42 patients with histologically confirmed, Barcelona Clinic Liver cancer (BCLC) stage B or C HCC will be enrolled on to this trial. Patients receive cobolimab 300 mg and dostarlimab 500 mg on day 1 of each 21-day cycle for up to two years or until disease progression, unacceptable toxicity, or patient withdrawal. CT or MRI is performed every 9 weeks to assess clinical response. The primary objective is to assess ORR. Results: At the cutoff date of September 1, 2022, 16 patients had been enrolled and received at least one dose of cobolimab and dostarlimab. The median age was 68 years (range 44 – 84); most were male (n=15); 5 were White, 5 Native Hawaiian, 4 Asian, and 2 other races. 3 patients had stage BCLC B and 13 had stage BCLC C disease; 1 had Hep B and 5 had Hep C; and 14 were Child Pugh A and 2 Child Pugh B. This interim analysis for efficacy includes 13 patients who had at least one post-baseline tumor assessment (or clinical progression or died). Complete response was seen in 1 patient, partial response in 5 patients (ORR 46%), stable disease in 3 patients (23%), and disease progression in 4 patients (31%). Of the 7 patients with an elevated AFP at baseline, 4 (57%) had a decrease in AFP level by greater than 50%. There was one grade 4 treatment-related adverse event (AE) of neutropenia. Grade 1/2 AEs included pruritus, rash, fatigue, hypothyroidism, and elevated AST and ALT. Conclusions: Interim results indicate that the combination of cobolimab and dostarlimab has acceptable safety with encouraging clinical activity as first line treatment in patient with advanced HCC. To our knowledge, this is the first report of clinically meaningful efficacy of a TIM-3 antibody in combination with a PD-1 antibody in patients with HCC. Clinical trial information: NCT03680508 .

Funder

GlaxoSmithKline

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3